Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition

RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition

US Patent 11739326 · Granted Aug 29, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliver2025
Anti-ApoE antibodies and polynucleotides thereof2025
Blood biomarkers and diagnostic methods for small vessel diseases2025
Ophthalmic formulations of methotrexate2024
Ophthalmic formulations of methotrexate2024
Methods of delivering an agent to the eye2024
Methods of delivering an agent to the eye2024
Methotrexate treatment methods2024
Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery2023
Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery2023
NOTCH3 agonist compositions and methods for treating small vessel diseases2022
Compositions and methods for the treatment of aberrant angiogenesis2022